Antiretroviral therapy for children

Area of Science:

• Virology
• Pharmacology
• Pediatrics

Background:

• Human Immunodeficiency Virus type 1 (HIV-1) is the causative agent of Acquired Immunodeficiency Syndrome (AIDS).
• Significant progress in understanding retroviral replication and pathogenesis has driven antiviral drug development.
• Three antiretroviral drugs (Zidovudine, Didanosine, Zalcitabine) are now in routine human use, with experience in children for the first two.

Purpose of the Study:

• To review the current status and benefits of antiretroviral therapy (ART) for HIV-1 infection.
• To evaluate the rationale for and limitations of routine ART use in children.
• To discuss future strategies in antiviral drug development, including combination therapy.

Main Methods:

• Review of existing literature on HIV-1 antiviral drug development and clinical use.
• Analysis of benefits and toxicities of current antiretroviral agents.
• Discussion of ongoing research and future therapeutic strategies.

Main Results:

• ART offers significant benefits, including extended survival and reduced opportunistic infections in adults, and improved well-being in children.
• Current antiretroviral drugs can cause toxicities such as anemia, neutropenia, pancreatitis, and neuropathy.
• Routine use of ART in asymptomatic children warrants further controlled studies due to potential cellular interference and toxicities.

Conclusions:

• Antiretroviral therapy is beneficial for symptomatic HIV-1 infection but requires careful consideration for asymptomatic children.
• Combination therapy is a promising strategy to maximize efficacy and minimize toxicity and drug resistance.
• Ongoing development of new antiviral agents and therapeutic strategies is crucial for managing HIV-1 infection.